Floatz logo

Rucaparib

Metastatic Biliary Tract Carcinoma

Academic and Community Cancer Research UnitedSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

84 Active assets in the Metastatic Biliary Tract Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Merck Sharp & Dohme LLC
Phase 3BB
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3BB
Epirubicin
Merck Sharp & Dohme LLC
Phase 3BB
Capecitabine
Zhejiang Cancer Hospital
Phase 2BB
FLUOROURACILUM
Shenzhen Xinhe Biomedical
Phase 2BB

View all 50 →

Same molecule, other indications

Rucaparib is also rated in:

peritoneum cancerDormant
BB
Indicative ·
66 / 100
View asset →
Metastatic Castration Resistant Prostate CancerDormant
BB
Indicative ·
64 / 100
View asset →
ovarian cancerDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →